Vaxart, Inc.
VXRT
OTC·Healthcare·Biotechnology·Mkt cap $121.0M
$0.50
▲ +1.52%
P/E
3.33
Mkt Cap
$121.0M
52-Wk Range
$0.31–$0.84
52-Week Range
$0.31 - $0.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 28.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-16.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying VXRT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.06 vs -$0.12 consensus (+50.0% surprise). Revenue of $27.2M vs $26.2M expected (+3.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+50.0%
Revenue trend · last 8Q
—
—
—
—
+1368%
+586%
+88%
-32%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.9M
$15.2M
$20.9M
$39.7M
$72.4M
$104.2M
$39.2M
$27.2M
Margins · last 8Q
Gross
0.0%
Operating
0.0%
Profit
-49.6%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How VXRT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.